Nemo Healthcare has developed the fetal monitoring system PUREtrace as an external measurement system which is able to measure contractions better in pregnant women before and during labor. The innovation contributes to the reduction of the two main causes of neonatal mortality, the lack of oxygen before or during birth (perinatal asphyxia) and death in premature birth. In the Netherlands these complications occur in approximately 15,000 cases annually (total number of births in 2012: 176,000).
Despite its non-invasive character, the used electrophysiological measurement technology offers highly accurate information on the uterine muscle activity that correlates with existing invasive measurement methods. PUREtrace can be connected to existing monitoring solutions used in hospitals.
The SME innovation top 100 is a yearly event organised by the Dutch Chamber of Commerce, NRC Media and Mercedes-Benz. Nemo Healthcare is nominated by innovation scouts based on the impact on the healthcare industry, innovation and availability. After being reviewed by an expert panel Nemo Healthcare is ranked 45th for the SME innovation top 100.
About Nemo Healthcare
Nemo Healthcare is a Dutch high-tech startup company that focuses on the development of innovative technology for pregnancy monitoring. Nemo is characterized by its unique combination of specialized expertise in the fields of technology, science and medicine and its solid network of development partners. This enables Nemo Healthcare to further develop state-of-the-
Visit http://www.nemohealthcare.com for more details.